...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Long‐term effects: Galectin‐1 and specific immunotherapy for allergic responses in the intestine
【24h】

Long‐term effects: Galectin‐1 and specific immunotherapy for allergic responses in the intestine

机译：长期影响：Galectin-1和特异性免疫疗法在肠中过敏反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background and Aims Mast cell activation interferes with the effects of allergen‐specific immunotherapy ( SIT ). Galectin‐1 (Gal‐1) is capable of regulating immune cells’ functions. This study tests the hypothesis that administration of Gal‐1 promotes and prolongs the efficacy of SIT via suppressing mast cell activation. Methods An intestinal allergy mouse model was developed. The coadministration of SIT and Gal‐1 on suppression of the allergic responses, prevention of mast cell activation, and generation of antigen‐specific regulatory T cells (Treg) in the intestine was observed in sensitized mice. Results The coadministration of Gal‐1 and SIT markedly suppressed the allergic responses in the mouse intestine vs the use of either SIT alone or Gal‐1 alone. The Gal‐1 binds to the IgE/Fc? RI complexes on the surface of mast cells to prevent mast cell activation during SIT . Gal‐1 promoted the SIT ‐generated allergen‐specific Tregs in the intestine of sensitized mice. Coadministration of Gal‐1 and SIT significantly enhanced the efficacy of immunotherapy in suppressing allergic responses in the intestine, which lasted for at least for 12?months. Conclusions Long‐term effects of specific immunotherapy on intestinal allergy can be achieved with Gal‐1/ SIT therapy by inhibiting mast cell activation and facilitating Treg development.
机译：摘要背景和AIMS肥大细胞活化干扰过敏原特异性免疫疗法的影响（坐下）。 Galectin-1（Gal-1）能够调节免疫细胞的功能。该研究测试了通过抑制肥大细胞活化促进Gal-1的假设促进并延长静脉静脉静脉的功效。方法开发了肠道过敏鼠标模型。在敏化小鼠中观察到静坐和加仑抑制过敏反应，预防肥大细胞活化，抗原特异性调节T细胞（Treg）的抑制的共同作用。结果GAL-1的共同性，坐下，抑制了小鼠肠中的过敏反应与单独使用或单独的GAL-1使用。 gal-1与IgE / Fc结合？ RI复合物在桅杆细胞表面上，以防止静坐肥大细胞活化。 GAL-1在敏化小鼠的肠道中促进了特异性的过敏原特异性Treg。 GAL-1的共同分析并静置显着提高了免疫疗法在抑制肠中过敏反应的功效，该含量持续至少为12个月。结论通过抑制肥大细胞活化和促进Treg发育，可以通过GAL-1 / SIT治疗实现特异性免疫疗法对肠道过敏的长期影响。

著录项

  • 来源
    《Allergy》 |2018年第1期|共9页
  • 作者

    Yang L.‐T.; Shu Q.; Luo X.‐Q.; Liu Z.‐Q.; Qiu S.‐Q.; Liu J.‐Q.; Guo H.‐J.; Li L.‐J.; Li M.‐G.; Liu D.‐B.; Xia L.‐X.; Liu Z.‐G.; Yang P.‐C.;

  • 作者单位

    The Research Center of Allergy &

    ImmunologyShenzhen University School of MedicineShenzhen China;

    The Department of GastroenterologyShenzhen UniversityShenzhen China;

    Department of Pediatric OtolaryngologySouthern Medical UniversityShenzhen China;

    The Research Center of Allergy &

    ImmunologyShenzhen University School of MedicineShenzhen China;

    Shenzhen ENT InstituteAffiliated ENT Hospital of Shenzhen UniversityShenzhen China;

    The Research Center of Allergy &

    ImmunologyShenzhen University School of MedicineShenzhen China;

    The Department of GastroenterologyShenzhen UniversityShenzhen China;

    Brain Body InstituteMcMaster UniversityHamilton ON Canada;

    The Research Center of Allergy &

    ImmunologyShenzhen University School of MedicineShenzhen China;

    Department of Pediatric OtolaryngologySouthern Medical UniversityShenzhen China;

    The Research Center of Allergy &

    ImmunologyShenzhen University School of MedicineShenzhen China;

    The Research Center of Allergy &

    ImmunologyShenzhen University School of MedicineShenzhen China;

    The Research Center of Allergy &

    ImmunologyShenzhen University School of MedicineShenzhen China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

    allergy; galectin‐1; immune regulation; mast cells; specific immunotherapy;

    机译：过敏;Galectin-1;免疫调节;肥大细胞;特定免疫疗法;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号